Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Avutometinib Plus Defactinib Signals Changing Tides in Low-Grade Serous Ovarian Cancer
Revisit the OncLive On Air Episodes From February 2024
Awareness and Early Detection Remain Key Issues in Ovarian Cancer
Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer